Onchilles Pharma was founded on breakthrough research of a novel neutrophil pathway that when activated selectively and comprehensively kills cancer cells. Based on this research, the private biotech company is developing a pipeline of first-in-class drug candidates that have the potential to be broadly effective against a wide range of cancers.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/10/25 | $25,000,000 | Series A-1 |
InVivium Capital Kennedy Lewis Investment Management Lincoln Park Capital LYZZ Capital UCM Ventures | undisclosed |
